Biller Beverly M K
Neuroendocrine Clinical Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Horm Res. 2007;68 Suppl 5:59-65. doi: 10.1159/000110478. Epub 2007 Dec 10.
To make a diagnosis of growth hormone deficiency (GHD), individuals with normal GH levels must be distinguished from those who are deficient. This requires an understanding of how GH secretion and other related factors differs between these two groups. The presence of a normal insulin-like growth factor I (IGF-I) level does not necessarily preclude a diagnosis of GHD, whereas a low IGF-I level in a subject with three or four other hormone deficiencies and no conditions that would otherwise lower IGF-I might be sufficient to make the diagnosis. Provocative testing is a clinically relevant method of testing, but not all tests in use have comparable specificity and sensitivity.
Insulin-induced hypoglycemia is the recommended test to diagnose GHD, but the arginine-GH-releasing hormone test achieves comparable separation between normal and hypopituitary subjects in most groups. Future studies using large surveillance databases may further expand our understanding of concepts underlying GHD and its diagnosis.
为了诊断生长激素缺乏症(GHD),必须将生长激素(GH)水平正常的个体与缺乏GH的个体区分开来。这需要了解这两组人群中GH分泌及其他相关因素的差异。胰岛素样生长因子I(IGF-I)水平正常并不一定排除GHD的诊断,而在伴有其他三种或四种激素缺乏且无其他可降低IGF-I水平情况的受试者中,IGF-I水平较低可能足以做出诊断。激发试验是一种具有临床相关性的检测方法,但并非所有正在使用的检测方法都具有可比的特异性和敏感性。
胰岛素诱导的低血糖是诊断GHD的推荐检测方法,但精氨酸-生长激素释放激素试验在大多数人群中能在正常人和垂体功能减退者之间实现类似的区分。未来使用大型监测数据库的研究可能会进一步拓展我们对GHD及其诊断背后概念的理解。